24,571 Shares in Gossamer Bio, Inc. (NASDAQ:GOSS) Bought by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP acquired a new position in Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 24,571 shares of the company’s stock, valued at approximately $294,000.

Other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd bought a new stake in shares of Gossamer Bio in the first quarter worth $33,000. Great West Life Assurance Co. Can acquired a new position in Gossamer Bio in the third quarter valued at $57,000. Corton Capital Inc. acquired a new position in Gossamer Bio in the second quarter valued at $91,000. Sequoia Financial Advisors LLC acquired a new position in Gossamer Bio in the third quarter valued at $132,000. Finally, Delphia USA Inc. acquired a new position in Gossamer Bio in the second quarter valued at $100,000. Institutional investors own 90.18% of the company’s stock.

Gossamer Bio Stock Up 6.0 %

Shares of NASDAQ GOSS opened at $1.76 on Friday. The stock has a market capitalization of $166.28 million, a P/E ratio of -0.61 and a beta of 1.25. The company has a 50-day moving average price of $2.20 and a 200-day moving average price of $7.71. Gossamer Bio, Inc. has a 1 year low of $1.57 and a 1 year high of $15.20. The company has a debt-to-equity ratio of 3.73, a current ratio of 5.93 and a quick ratio of 5.93.

Analyst Ratings Changes

Several research firms recently issued reports on GOSS. Raymond James dropped their target price on shares of Gossamer Bio from $18.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, November 17th. HC Wainwright decreased their price target on shares of Gossamer Bio from $25.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, December 8th. Evercore ISI decreased their price target on shares of Gossamer Bio to $7.00 in a research note on Monday, December 12th. SVB Leerink decreased their price target on shares of Gossamer Bio from $15.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, December 7th. Finally, Sumitomo Mitsui Financial Group downgraded shares of Gossamer Bio from an “outperform” rating to a “neutral” rating and set a $3.00 price target for the company. in a research note on Wednesday, December 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.25.

Gossamer Bio Profile

(Get Rating)

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.